Jorna Therapeutics
Yong Dai is a prominent figure in the biotechnology and therapeutics sectors, currently serving as President, Co-Founder, and Executive Board Director at Jorna Therapeutics, which focuses on advanced genome and transcriptome editing using innovative technologies. Additional roles include membership on the Scientific Advisory Boards of Juvensis Therapeutics and Synphatec Biosciences, as well as a Venture Partner at NHH Ventures. Yong Dai previously led Frontera Therapeutics as CEO and Founder, specializing in gene therapy therapeutics, and held significant positions at Prevail Therapeutics and uniQure, contributing to the development of gene therapies for neurodegenerative disorders and severe genetic diseases, respectively. Educational credentials include a Ph.D. in Biochemistry and Molecular Biology from the Chinese Academy of Sciences, and a Postdoctoral Fellowship from Harvard University.
This person is not in any teams
Jorna Therapeutics
Jorna is a Quantum Sky company. We use Quantum Sky’s AI to generate DNA/RNA editors, and apply them to develop previously unattainable treatments.